Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6UXT8
UPID:
ALKL1_HUMAN
Alternative names:
Augmentor beta
Alternative UPACC:
Q6UXT8; B7ZMG9
Background:
ALK and LTK ligand 1, also known as Augmentor beta, is a pivotal cytokine that specifically activates receptor tyrosine kinase LTK through binding and homodimerization. This process is crucial for the physiological function of LTK, distinguishing ALKAL1 from ALKAL2, which does not significantly activate ALK.
Therapeutic significance:
Understanding the role of ALK and LTK ligand 1 could open doors to potential therapeutic strategies. Its unique interaction with LTK suggests a targeted approach in diseases where LTK signaling is implicated.